93 سنت
الانسايدر شراء شهر يناير
عليها خبر اليوم
Viragen Files to Expand Cancer Approval for Multiferon(R) in Sweden
PR Newswire - February 04, 2005 10:37
Additional European Applications Expected To Follow
PLANTATION, Fla., Feb 04, 2005 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) and its majority-owned subsidiary, Viragen International, Inc. (OTC Bulletin Board: VGNI), today announced that an application has been filed with the Swedish regulatory authorities seeking to expand the approval for Multiferon(R) to include the first-line adjuvant treatment of high-risk malignant melanoma, following dacarbazine (DTIC) after surgical removal of tumors. This submission represents the initial step of the Company's plans to seek broader European approvals for Multiferon(R).
المفضلات